1
|
Tatarczuch M, Waltham M, Shortt J, Hawkes E, Ho SJ, Trotman J, Brasacchio D, Co M, Li J, Ramakrishnan V, Dunne K, Opat S, Gregory G. P1261: ALLG LABORATORY SCIENCE STUDY LS21: MOLECULAR CORRELATES OF RESPONSE IN RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (RRMZL) PATIENTS TREATED WITH ZANUBRUTINIB IN THE MAGNOLIA TRIAL. Hemasphere 2022. [PMCID: PMC9430053 DOI: 10.1097/01.hs9.0000847908.60002.1c] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
2
|
Hapgood G, Latimer M, Lee ST, Kuss B, Lade S, Tobin JWD, Purtill D, Campbell BA, Prince HM, Hawkes EA, Shortt J, Radeski D. Diagnosis, management and follow up of peripheral T cell lymphomas: A Consensus Practice Statement from the Australasian Lymphoma Alliance. Intern Med J 2021; 52:1806-1817. [PMID: 34668281 DOI: 10.1111/imj.15595] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2021] [Revised: 09/14/2021] [Accepted: 10/09/2021] [Indexed: 11/30/2022]
Abstract
Peripheral T-cell lymphomas (PTCLs) represent a heterogeneous disease group accounting for 10% of non-Hodgkin lymphomas. PTCL patients have typically poorer outcomes compared to aggressive B-cell lymphomas. However, such outcomes are heavily dependent upon subtype. Although anthracycline-based regimens such as cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) remain the standard first-line treatment for most aggressive PTCLs, there are important variations including incorporation of novel agents, use of radiotherapy and judicious consideration of stem cell transplantation. Relapsed or refractory disease represents a significant area of unmet need where chemotherapy intensification has limited efficacy and novel agents such as brentuximab vedotin and pralatrexate provide additional opportunities for attainment of remission and potential stem cell transplant. In the future, pre-therapy prognostic biomarkers including genomic characterisation, may aid in risk stratification and help guide initial patient management to improve survival. There is an urgent need to better understand the pathogenesis of PTCLs to facilitate novel drug combinatorial approaches to improve survival. This position statement represents an evidence-based synthesis of the literature for application in Australian and New Zealand practice. This article is protected by copyright. All rights reserved.
Collapse
Affiliation(s)
- G Hapgood
- Princess Alexandra Hospital, Brisbane, Australia.,University of Queensland, Brisbane, Australia
| | - M Latimer
- The Canberra Hospital, Canberra, Australia
| | - S T Lee
- Olivia Newton John Cancer Research Institute, Austin Health, Melbourne, Australia.,University of Melbourne, Melbourne, Victoria, Australia
| | - B Kuss
- Flinders University, Bedford Park, Australia.,Flinders Medical Centre, Bedford Park, Australia
| | - S Lade
- Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
| | - J W D Tobin
- Mater Health, South Brisbane, Australia.,Mater Research Institute, University of Queensland, Brisbane, Australia
| | - D Purtill
- University of Western Australia, Perth, Australia.,Fiona Stanley Hospital, Perth, Australia
| | - B A Campbell
- University of Melbourne, Melbourne, Victoria, Australia.,Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
| | - H M Prince
- University of Melbourne, Melbourne, Victoria, Australia.,Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
| | - E A Hawkes
- Olivia Newton John Cancer Research Institute, Austin Health, Melbourne, Australia.,University of Melbourne, Melbourne, Victoria, Australia
| | - J Shortt
- Monash University, Clayton, Australia.,Monash Health, Clayton, Australia
| | - D Radeski
- University of Western Australia, Perth, Australia.,Sir Charles Gairdner Hospital, Nedlands, Australia
| |
Collapse
|
3
|
Hilton-Proctor J, Ilyichova O, Zheng Z, Jennings I, Johnstone R, Shortt J, Mountford S, Scanlon M, Thompson P. Synthesis and elaboration of N-methylpyrrolidone as an acetamide fragment substitute in bromodomain inhibition. Bioorg Med Chem 2019; 27:115157. [DOI: 10.1016/j.bmc.2019.115157] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2019] [Revised: 10/07/2019] [Accepted: 10/08/2019] [Indexed: 01/24/2023]
|
4
|
Casan J, Wolyncewicz G, Alam W, Opat S, Gregory G, Shortt J, Patil S, Gilbertson M. R-IVAC SALVAGE THERAPY IN RELAPSED AND REFRACTORY DLBCL. Hematol Oncol 2019. [DOI: 10.1002/hon.110_2631] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- J. Casan
- Haematology; Monash Health; Clayton Australia
| | | | - W. Alam
- Haematology; Monash Health; Clayton Australia
| | - S. Opat
- School of Clinical Sciences at Monash Health; Monash University; Clayton Australia
| | - G. Gregory
- School of Clinical Sciences at Monash Health; Monash University; Clayton Australia
| | - J. Shortt
- School of Clinical Sciences at Monash Health; Monash University; Clayton Australia
| | - S. Patil
- Haematology; The Alfred Hospital; Melbourne Australia
| | | |
Collapse
|
5
|
Gregory G, Walker P, Mahadevan D, Wang D, Chang J, Hernandez-Ilizaliturri F, Klein A, Rybka W, Wagner-Johnston N, Escobar C, Pagel J, Mohrbacher A, Opat S, Shortt J, Ma H, Gwo J, Farooqui M, Quach H. ANTITUMOR ACTIVITY OF PEMBROLIZUMAB PLUS DINACICLIB IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA: THE PHASE 1B KEYNOTE-155 STUDY. Hematol Oncol 2019. [DOI: 10.1002/hon.140_2630] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- G. Gregory
- Hematology; School of Clinical Sciences at Monash Health, Monash University; Clayton Australia
| | - P. Walker
- Clinical; Peninsula Health; Frankston Australia
| | - D. Mahadevan
- Medicine; The University of Arizona Cancer Center; Tucson United States
| | - D. Wang
- Hematology/Oncology; Henry Ford Hospital; Detroit United States
| | - J. Chang
- Oncology; Wisconsin Institute of Medical Research; Madison United States
| | | | - A. Klein
- Hematology/Oncology; Tufts Medical Center; Boston United States
| | - W. Rybka
- Oncology; Penn State Hershey Cancer Institute; Hershey United States
| | - N. Wagner-Johnston
- Oncology; Johns Hopkins Sidney Kimmel Cancer Center; Baltimore United States
| | - C. Escobar
- Oncology; Baylor University Medical Center; Dallas United States
| | - J.M. Pagel
- Hematology; Swedish Cancer Institute; Seattle United States
| | - A. Mohrbacher
- Hematology; Keck School of Medicine of USC; Los Angeles United States
| | - S. Opat
- Hematology; School of Clinical Sciences at Monash Health, Monash University; Clayton Australia
| | - J. Shortt
- Hematology; School of Clinical Sciences at Monash Health, Monash University; Clayton Australia
| | - H. Ma
- Biostatistics; Merck & Co., Inc.; Kenilworth NJ United States
| | - J. Gwo
- Biostatistics; Merck & Co., Inc.; Kenilworth NJ United States
| | - M. Farooqui
- Clinical Research; Merck & Co., Inc.; Kenilworth United States
| | - H. Quach
- Hematology; University of Melbourne, St. Vincent's Hospital; Fitzroy Australia
| |
Collapse
|
6
|
West AC, Martin BP, Andrews DA, Hogg SJ, Banerjee A, Grigoriadis G, Johnstone RW, Shortt J. The SMAC mimetic, LCL-161, reduces survival in aggressive MYC-driven lymphoma while promoting susceptibility to endotoxic shock. Oncogenesis 2016; 5:e216. [PMID: 27043662 PMCID: PMC4848837 DOI: 10.1038/oncsis.2016.26] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2016] [Revised: 02/29/2016] [Accepted: 02/29/2016] [Indexed: 12/24/2022] Open
Abstract
Inhibitor of apoptosis proteins (IAPs) antagonize caspase activation and regulate death receptor signaling cascades. LCL-161 is a small molecule second mitochondrial activator of caspase (SMAC) mimetic, which both disengages IAPs from caspases and induces proteasomal degradation of cIAP-1 and -2, resulting in altered signaling through the NFκB pathway, enhanced TNF production and sensitization to apoptosis mediated by the extrinsic pathway. SMAC mimetics are undergoing clinical evaluation in a range of hematological malignancies. Burkitt-like lymphomas are hallmarked by a low apoptotic threshold, conveying sensitivity to a range of apoptosis-inducing stimuli. While evaluating LCL-161 in the Eμ-Myc model of aggressive Burkitt-like lymphoma, we noted unexpected resistance to apoptosis induction despite ‘on-target' IAP degradation and NFκB activation. Moreover, LCL-161 treatment of lymphoma-bearing mice resulted in apparent disease acceleration concurrent to augmented inflammatory cytokine-release in the same animals. Indiscriminate exposure of lymphoma patients to SMAC mimetics may therefore be detrimental due to both unanticipated prolymphoma effects and increased susceptibility to endotoxic shock.
Collapse
Affiliation(s)
- A C West
- Gene Regulation Laboratory, Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia.,Hudson Institute of Medical Research, Clayton, VIC, Australia.,Department of Molecular and Translational Sciences, Monash University, Clayton, VIC, Australia
| | - B P Martin
- Gene Regulation Laboratory, Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia
| | - D A Andrews
- Department of Microbiology & Immunology, Central Clinical School, Monash University, Clayton, VIC, Australia
| | - S J Hogg
- Gene Regulation Laboratory, Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia.,Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, Australia
| | - A Banerjee
- Hudson Institute of Medical Research, Clayton, VIC, Australia.,Centre for Inflammatory Diseases, Monash University, Clayton, VIC, Australia
| | - G Grigoriadis
- Hudson Institute of Medical Research, Clayton, VIC, Australia.,Alfred Pathology Service, Alfred Health, Prahran, VIC, Australia.,Monash Haematology, Monash Health, Clayton, VIC, Australia.,School of Clinical Sciences, Monash Health, Monash University, Clayton, VIC, Australia
| | - R W Johnstone
- Gene Regulation Laboratory, Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia.,Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, Australia
| | - J Shortt
- Gene Regulation Laboratory, Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia.,Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, Australia.,Monash Haematology, Monash Health, Clayton, VIC, Australia.,School of Clinical Sciences, Monash Health, Monash University, Clayton, VIC, Australia
| |
Collapse
|
7
|
Affiliation(s)
- S J Hogg
- Cancer Therapeutics Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia
| | - R W Johnstone
- Cancer Therapeutics Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia
| | - J Shortt
- Cancer Therapeutics Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia Monash Haematology, Monash Health, Clayton, Victoria, Australia School of Clinical Sciences at Monash Health; Faculty of Medicine, Nursing and Health Sciences; Monash University, Clayton, Victoria, Australia
| |
Collapse
|
8
|
Wolyniec K, Shortt J, Opat S, Johnstone R, Scott C, Fox S, Strasser A, Haupt S, Haupt Y. 178 E6AP Ubiquitin Ligase Regulates PML-induced Senescence in Myc-driven Lymphomagenesis. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)70877-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
9
|
Shortt J, Opat SS, Gorniak MB, Aumann HA, Collecutt MF, Street AM. A retrospective study of the utility of desmopressin (1-deamino-8-D-arginine vasopressin) trials in the management of patients with von Willebrand disorder. Int J Lab Hematol 2010; 32:e181-3. [DOI: 10.1111/j.1751-553x.2008.01117.x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
10
|
|
11
|
Shortt J, Westall GP, Roxby D, Chen JW, Snell GI, Polizzotto MN, Magrin G, Webb A, Street AM, Borosak M, Wood EM, Cole-Sinclair MF. A 'dangerous' group O donor: severe hemolysis in all recipients of organs from a donor with multiple red cell alloantibodies. Am J Transplant 2008; 8:711-4. [PMID: 18294168 DOI: 10.1111/j.1600-6143.2007.02113.x] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Alloimmune hemolysis is a recognized but infrequent complication of solid organ transplantation, particularly where there is incompatibility within the ABO blood group system. We describe severe hemolysis due to passenger lymphocyte syndrome (PLS) in all three recipients of organs from a single donor with multiple red cell (RC) alloantibodies. The first patient, a liver transplant recipient, required augmentation of immunosuppression to treat immune hemolysis due to anti-B, -D, -C and -Cellano (k). This is the first description of PLS caused by alloantibody to the high incidence RC antigen, k. The two single lung transplant recipients developed hemolysis due to anti-D. Both required escalation of immunosuppression and early transfusion support. Three months posttransplant, all three patients have ongoing evidence of compensated hemolysis. This series highlights the potential for severe non-ABO-mediated immune hemolysis following solid organ transplantation. A positive donor RC antibody screen should prompt careful monitoring of organ recipients for hemolysis.
Collapse
Affiliation(s)
- J Shortt
- Haematology Unit, Alfred Pathology Service, Alfred Hospital, Melbourne, Australia.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Kalff A, Shortt J, Farr J, McLennan R, Lui A, Scott J, Spencer A. Laboratory tumor lysis syndrome complicating LBH589 therapy in a patient with acute myeloid leukaemia. Haematologica 2008; 93:e16-7. [DOI: 10.3324/haematol.11933] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
|
13
|
|
14
|
Shortt J, Dunkley S, Rickard K, Baker R, Street A. Efficacy and safety of a high purity, double virus inactivated factor VIII/von Willebrand factor concentrate (Biostate�) in patients with von Willebrand disorder requiring invasive or surgical procedures. Haemophilia 2007; 13:144-8. [PMID: 17286766 DOI: 10.1111/j.1365-2516.2006.01430.x] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Abstract
Biostate is a double virally inactivated, plasma derived coagulation factor VIII (FVIII)/von Willebrand factor (VWF) concentrate registered and used in Australia, New Zealand and Asia for the treatment of patients with haemophilia A. Although Biostate has been well characterized for FVIII and VWF (ratio 1:2 respectively) and shows a similar VWF multimeric pattern to normal plasma, limited published data is available on its clinical efficacy and safety in patients with von Willebrand disorder (VWD) who require surgical procedures. We retrospectively assessed the efficacy and safety of Biostate in all VWD patients treated at three Australian haemophilia treatment centres undergoing invasive procedures or surgery over a 29-month period between April 2003 and September 2005. A chart review of 43 VWD patients (26 VWD type 1, 12 VWD type 2, 5 VWD type 3; 21 male, 22 female; mean age 52 years, range 19-80 years) undergoing 58 surgical procedures (24 major, 34 minor) was performed. For each procedure, data were collected on Biostate dosage and administration, adverse reactions, haemostatic efficacy and bleeding events. Haemostatic efficacy of Biostate was assessed as excellent in 78% or good in 22% of procedures. There were no bleeding events attributable to lack of efficacy in any patients. No adverse reactions related to the administration of Biostate were observed. These results suggest that Biostate is both safe and efficacious for the prevention of excessive bleeding in VWD patients undergoing surgery or invasive procedures.
Collapse
Affiliation(s)
- J Shortt
- Alfred Hospital, Melbourne, Vic., Australia.
| | | | | | | | | |
Collapse
|
15
|
Shortt J, Spencer A. Adjuvant rituximab causes prolonged hypogammaglobulinaemia following autologous stem cell transplant for non-Hodgkin's lymphoma. Bone Marrow Transplant 2006; 38:433-6. [PMID: 16892074 DOI: 10.1038/sj.bmt.1705463] [Citation(s) in RCA: 53] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Rituximab is an anti-CD20 monoclonal antibody that has efficacy in B-cell non-Hodgkin's lymphoma (NHL). Adjuvant immunotherapy with rituximab may reduce relapse rates for high-risk B-cell NHL following high-dose chemotherapy with autologous stem cell transplantation (SCT). However, the potential adverse effects of rituximab on immune reconstitution following SCT are not fully characterized. We performed a retrospective analysis of immunoglobulin (Ig) levels and peripheral blood neutrophil counts in 11 patients who received adjuvant rituximab following autologous SCT for B-cell NHL. Results were compared to a contemporaneous group of 24 patients who received an identical conditioning regimen and autologous SCT for lymphoma, but no adjuvant rituximab. Adjuvant rituximab was associated with a significantly increased incidence of hypogammaglobulinaemia between 12 and 24 months post-SCT, but not neutropenia. Despite suppression of Igs, there were no late or atypical infective complications attributable to rituximab.
Collapse
MESH Headings
- Adjuvants, Pharmaceutic/administration & dosage
- Adjuvants, Pharmaceutic/adverse effects
- Adult
- Agammaglobulinemia/blood
- Agammaglobulinemia/etiology
- Aged
- Antibodies, Monoclonal/administration & dosage
- Antibodies, Monoclonal/adverse effects
- Antibodies, Monoclonal, Murine-Derived
- Antineoplastic Agents/administration & dosage
- Antineoplastic Agents/adverse effects
- Female
- Humans
- Immunoglobulin G/blood
- Immunotherapy/adverse effects
- Leukocyte Count
- Lymphoma, B-Cell/blood
- Lymphoma, B-Cell/complications
- Lymphoma, B-Cell/etiology
- Male
- Middle Aged
- Retrospective Studies
- Rituximab
- Stem Cell Transplantation/adverse effects
- Transplantation, Autologous
Collapse
Affiliation(s)
- J Shortt
- Department of Clinical Haematology and Bone Marrow Transplantation, Alfred Hospital, Melbourne, Victoria, Australia.
| | | |
Collapse
|
16
|
Shortt J, Hart DN, Watson JD, Baird MA. Blockade of B7-2, not B7-1, inhibits purified protein derivative-primed T-lymphocyte responses but fails to influence the proportion of Th1 versus Th2 subsets. Scand J Immunol 1998; 47:355-62. [PMID: 9600317 DOI: 10.1046/j.1365-3083.1998.00315.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
The ability to select for a cell-mediated response rather than antibody production following infection with intracellular mycobacteria, would be an advantage in preventing the occurrence of disease. Recent work suggests that the two members of the B7 family of costimulatory molecules, B7-1 and B7-2, may differentially influence the nature of primary immune responses but little is known of their role in this capacity in secondary responses. We have used an in vitro model to investigate whether blocking B7-1 and B7-2 affects changes in the cytokine profiles of Th lymphocytes previously primed to purified protein derivative (PPD) from Mycobacterium bovis. In C57BL/6 and BALB/c mice we found that the proliferative responses of a component of recently activated T lymphocytes, and those returning to the resting state, were inhibited by B7-2 blockade. B7-1 blockade had no distinguishable effect. However, in cultures containing anti-B7-2 antibody, the production of both interferon-gamma (IFN-gamma) and interleukin-4 (IL-4), indicative of cell-mediated and antibody responses, respectively, were reduced. This suggests that intervention in a recall response to mycobacterial antigen by blocking B7-1 or B7-2 molecules, is unlikely to alter the nature of the immune response.
Collapse
Affiliation(s)
- J Shortt
- Department of Pathology, Dunedin School of Medicine, New Zealand
| | | | | | | |
Collapse
|
17
|
Shortt J. Canada's health care system: the good, the bad, and the ugly. J Med Assoc Ga 1993; 82:301-4. [PMID: 8326245] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Affiliation(s)
- J Shortt
- Piedmont Orthopaedic and Sports Medicine Complex, Macon, GA 31210
| |
Collapse
|
18
|
Shortt J. Think before you have to fight. Nurs Mirror 1982; 154:11. [PMID: 6919061] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
|